This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural As pharmaceutical companies race to scale synthetic GLP-1s, Evolv is betting that consumers want a natural, orally available version. Previous Article How Will the Economy Perform in 2026? These 7 People Will Tell You. Next Article Working on Your Pincha Mayurasana? Here’s How to Prep for Forearm Stand.
